Anti-proliferative effect of rosiglitazone on angiotensin II-induced vascular smooth muscle cell proliferation is mediated by the mTOR pathway

Cell Biology International

Volumn 36, Issue 3, 2012, Pages 305-310

  Kim, Jung Sun ^a   Kim, Il Kwon ^b   Lee, Se Yeon ^b   Song, Byeong Wook ^b   Cha, Min Ji ^b   Song, Heesang ^c   Choi, Eunmi ^b   Lim, Soyeon ^b   Ham, Onju ^b   Jang, Yangsoo ^a,b   Hwang, Ki Chul ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Chosun University   (South Korea)

Author keywords

Angiotensin II; Mammalian target of rapamycin (mTOR); Proliferation; Rosiglitazone; Smooth muscle cell

Indexed keywords

ANGIOTENSIN II; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; INITIATION FACTOR 4E BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; ROSIGLITAZONE; S6 KINASE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANTIPROLIFERATIVE ACTIVITY; AORTA; ARTICLE; CELL ISOLATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; IMMUNOBLOTTING; NONHUMAN; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ANGIOTENSIN II; ANIMALS; CELL PROLIFERATION; MUSCLE, SMOOTH, VASCULAR; RATS; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TOR SERINE-THREONINE KINASES;

EUKARYOTA; MAMMALIA; RATTUS;

EID: 84859240796     PISSN: 10656995     EISSN: 10958355     Source Type: Journal    
DOI: 10.1042/CBI20100524     Document Type: Article

References (27)

1. Arellano-Plancarte A, Hernandez-Aranda J, Catt KJ, Olivares-Reyes JA. Angiotensin-induced EGF receptor transactivation inhibits insulin signaling in C9 hepatic cells. Biochem Pharmacol 2010;79:733-45.
2. Benkirane K, Amiri F, Diep Q, El Mabrouk M, Schiffrin EL. PPAR inhibits angiotensin II-induced cell growth via SHIP2 and 4E-BP1. Am J Physiol Heart Circ Physiol 2006a;290:H390-7.
3. Benkirane K, Viel EC, Amiri F, Schiffrin EL. Peroxisome proliferatoractivated receptor regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo. Hypertension 2006b;47:102-8.
4. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002;53:409-35.
5. Brassard P, Amiri F, Schiffrin EL. Combined angiotensin II type 1 and type 2 receptor blockade on vascular remodeling and matrix metalloproteinases in resistance arteries. Hypertension 2005;46:598-606.
6. Bruemmer D, Law RE. Thiazolidinediones regulation of smooth muscle cell proliferation. Am J Med 2003;115:87S-92S.
7. Cho DH, Choi YJ, Jo SA, Ryou J, Kim JY, Chung J et al. Troglitazone acutely inhibits protein synthesis in endothelial cells via a novel mechanism involving protein phosphatase 2A-dependent p70 S6 kinase inhibition. Am J Physiol Cell Physiol 2006;291:C317-26.
8. Choi D, Kim SK, Choi SH, Ko YG, Ahn CW, Jang Y et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004;27:2654-60.
9. Dugourd C, Gervais M, Corvol P, Monnot C. Akt is a major downstream target of PI3-kinase involved in angiotensin II-induced proliferation. Hypertension 2003;41:882-90.
10. Gao DF, Niu XL, Hao GH, Peng N, Wei J, Ning N et al. Rosiglitazone inhibits Ang II-induced CTGF expression in vascular smooth muscle cells - role of PPAR-gamma in vascular fibrosis. Biochem Pharmacol 2007;73:185-97.
11. Goetze S, Xi XP, Graf K, Fleck E, Hsueh WA, Law RE. Troglitazone inhibits Ang II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells. FEBS Lett 1999;452:277-82.
12. Hafizi S, Wang X, Chester AH, Yacoub MH, Proud CG. Ang II activates effectors of m-TOR via PI3-K signaling in human coronary smooth muscle cells. Am J Physiol Heart Circ Physiol 2004;287:H1232-8.
13. Horiuchi M, Cui TX, Li Z, Li JM, Nakagami H, Iwai M. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation 2003;107:106-12.
14. Ji Y, Liu J, Wang Z, Liu N, Gou W. PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation though the TLR4-dependent signaling pathway. Lab Invest 2009;89:887-902.
15. Jia G, Cheng G, Gangahar DM, Agrawal DK. Involvement of connexin 43 in angiotensin II-induced migration and proliferation of saphenous vein smooth muscle cells via the MAPK-AP-1 signaling pathway. J Mol Cell Cardiol 2008;44:882-90.
16. 2-stimulated rat aortic smooth muscle cells. Eur J Pharmacol 2004;484:119-25.
17. Lu J, Zhang J, Block ER, Patel JM. Angiotensin IV enhances phosphorylation of 4EBP1 by multiple signaling events in lung endothelial cells. Mol Cell Biochem 2005;275:181-8.
18. Mehta PK, Griendling KK. Ang II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007;292:C82-97.
19. Park S, Lim S, Chang W, Song H, Lee S, Song BW et al. The inhibition of insulin-stimulated proliferation of vascular smooth muscle cells by rosiglitazone is mediated by the Akt-mTOR-p70S6K pathway. Yonsei Med J 2008;49:592-600.
20. Perlegas D, Xie H, Sinha S, Somlyo AV, Owens GK. Ang II type 2 receptor regulates smooth muscle growth and force generation in late fetal mouse development. Am J Physiol Heart Circ Physiol 2005;288:H96-102.
21. Rosendorff C. The renin-angiotensin system and vascular hypertrophy. J Am Coll Cardiol 1996;28:803-12.
22. Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD. PPAR agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 2004;43:661-6.
23. Satani K, Konya H, Hamaguchi T, Umehara A, Katsuno T, Ishikawa T et al. Clinical significance of circulating hepatocyte growth factor, a new risk marker of carotid atherosclerosis in patients with Type 2 diabetes. Diabet Med 2006;23:617-22.
24. Touyz RM, Deng LY, He G, Wu XH, Schiffrin EL. Angiotensin II stimulates DNA and protein synthesis in vascular smooth muscle cells from human arteries: role of extracellular signal-regulated kinases. J Hypertens 1999a;17:907-16.
25. Touyz RM, El Mabrouk M, He G, Wu XH, Schiffrin EL. Mitogen-activated protein/extracellular signal-regulated kinase inhibition attenuates angiotensin II-mediated signaling and contraction in spontaneously hypertensive rat vascular smooth muscle cells. Circ Res 1999b;84:505-15.
26. Yamakawa T, Tanaka S, Kamei J, Kadonosono K, Okuda K. Phosphatidylinositol 3-kinase in angiotensin II-induced hypertrophy of vascular smooth muscle cells. Eur J Pharmacol 2003;478:39-46.
27. Zuo L, Ushio-Fukai M, Ikeda S, Hilenski L, Patrushev N, Alexander RW. Caveolin-1 is essential for activation of Rac1 and NAD(P)H oxidase after angiotensin II type 1 receptor stimulation in vascular smooth muscle cells: role in redox signaling and vascular hypertrophy. Arterioscler Thomb Vasc Biol 2005;25:1824-30.